Table II.

Association between the expression levels of histone modification markers and clinicopathological features in the stroma of endometrial cancer.

Clinicopathological characteristic	H3K27me3	P-valuea	H3K4me2	P-valueb	H3K4me3	P-valuec
FIGO stage		0.514		0.910		0.437
I	0.18±0.16		0.20±0.15		0.27±0.17
II–IV	0.15±0.13		0.20±0.07		0.22±0.17
Tumor grade		NS		NS		NS
G1	0.16±0.12		0.22±0.19		0.22±0.15
G2	0.08±0.03		0.17±0.05		0.26±0.18
G3	0.18±0.15		0.27±0.12		0.15±0.15
Type 2	0.19±0.28		0.12±0.08		0.41±0.30
Endometrial infiltration		NS		NS		NS
Limited to endometrium	0.15±0.18		0.08±0.06		0.34±0.27
<1/2	0.15±0.14		0.18±0.15		0.22±0.17
≥1/2	0.10±0.10		0.19±0.09		0.13±0.15
P53		0.394		0.112		0.032
Negative	0.16±0.15		0.19±0.14		0.20±0.15
Positive	0.10±0.07		0.09±0.08		0.36±0.25
ER		0.217		0.818		0.395
Negative	0.09±0.11		0.18±0.09		0.16±0.16
Positive	0.16±0.15		0.19±0.15		0.23±0.19
PR		0.096		0.877		0.163
Negative	0.03±0.04		0.20±0.13		0.10±0.14
Positive	0.16±0.15		0.19±0.14		0.23±0.19
LVSI		0.853		0.731		0.203
No	0.14±0.15		0.17±0.14		0.22±0.18
Yes	0.15±0.09		0.19±0.11		0.13±0.16

Data were presented as the mean ± standard deviation.

^aComparison between the level of H3K27me3 in the stroma of endometrial cancer in different indexes, such as FIGO stage I and FIGO stage II–IV.

^bComparison between the level of H3K4me2 in the stroma of endometrial cancer in different indexes.

^cComparison between the level of H3K4me3 in the stroma of endometrial cancer in different indexes. NS, no statistic difference; FIGO, International Federation of Gynecology and Obstetrics; ER, estrogen receptor; PR, progesterone receptor; LVSI, lymph-vascular space invasion; H3K27me3, histone H3 lysine 27 trimethylation; H3K4me2, histone H3 lysine 4 dimethylation; H3K4me3, histone H3 lysine 4 trimethylation.